Funding Clinical Trials

Funding Clinical Trials

Our Agency funds clinical trials testing promising stem cell or gene therapies for currently incurable diseases or disorders to help patients with unmet medical needs. For basic information about stem cell trials, visit our Clinical Trials 101 page. For a list of clinical trials that are a result of early-stage CIRM grants click here.

CIRM Clinical Dashboard

Disease Areas Investigator Organizationsort ascending Phase Trial Status Targeted Enrollment Detail
  • Bladder or Urinary Tract Disorder
James Yoo Wake Forest University Health Sciences Phase 1 Not yet recruiting 10
Howard Foyt ViaCyte, Inc. Phase 1/2 Closed 19
Manasi Jaiman ViaCyte, Inc. Phase 1/2 Active, not recruiting 75
Mark Humayun University of Southern California Phase 1 Active, not recruiting 16
Steven Deeks University of California, San Francisco Phase 1/2 Launching N/A
Mark Walters University of California, San Francisco Phase 1 Launching N/A
  • Severe Combined Immunodeficiency, Artemis deficient (ART-SCID)
Morton Cowan University of California, San Francisco Phase 1 Recruiting 25
  • Alpha Thalassemia Major
Tippi MacKenzie University of California, San Francisco Phase 1 Enrolling by invitation 10
Peter Stock University of California, San Francisco Phase 1/2 Recruiting 8
  • COVID-19
Michael Matthay University of California, San Francisco Phase 2 Active, not recruiting 120
Thomas Kipps University of California, San Diego Phase 1/2 Recruiting 138
Stephanie Cherqui University of California, San Diego Phase 1/2 Recruiting 6
Thomas Kipps University of California, San Diego Phase 1 Completed 26
Antoni Ribas University of California, Los Angeles Phase 1 Recruiting 12
  • Immune Disease
  • Pediatrics
  • X-linked Chronic Granulomatous Disease
Donald Kohn University of California, Los Angeles Phase 1/2 Active, not recruiting 16
Donald Kohn University of California, Los Angeles Phase 1 Recruiting 6
Steven Dubinett University of California, Los Angeles Phase 1 Recruiting 24
Donald Kohn University of California, Los Angeles Phase 2 Completed 10
  • Sarcoma
Theodore Nowicki University of California, Los Angeles Phase 1 Recruiting 12
  • Corneal Damage
Sophie Deng University of California, Los Angeles Phase 1 Recruiting 20
Dennis Slamon University of California, Los Angeles Phase 1 Completed 48
Henry Klassen University of California, Irvine Phase 1/2 Completed 28
  • Spina Bifida
Diana Farmer University of California, Davis Phase 1 Recruiting 55
Vicki Wheelock University of California, Davis Phase 1/2 Completed 29
  • Muscle Injury
Peter Belafsky University of California, Davis Phase 1/2 Recruiting 62
Mehrdad Abedi University of California, Davis Phase 1/2 Recruiting 18
Nancy Lane University of California, Davis Phase 1/2 Completed 58
Ivan King Tachyon Therapeutics, Inc Phase 1 Launching N/A
Robert Lowsky Stanford University Phase 1 Active, not recruiting 15
  • Anemia
  • Bone Marrow Transplant and Viral Infection
Alice Bertaina Stanford University Phase 1/2 Launching N/A
Gary Steinberg Stanford University Phase 1 Recruiting 30
Crystal Mackall Stanford University Phase 1 Recruiting 54
  • B cell cancers
  • Leukemia
  • Leukemia, Acute Myeloid (AML)
Maria Grazia Roncarolo Stanford University Phase 1 Recruiting 22
Joseph Wu Stanford University Phase 1 Recruiting 18
  • IPEX Syndrome
Rosa Bacchetta Stanford University Phase 1 Recruiting 36
David Miklos Stanford University Phase 1 Recruiting 60
Everett Meyer Stanford University Phase 1 Recruiting 22
Judith Shizuru Stanford University Phase 1/2 Recruiting 40
Irving Weissman Stanford University Phase 1 Completed 88
Stephen Gottschalk St. Jude Children's Research Hospital Phase 1/2 Recruiting 28
  • Beta Thalassemia
Bettina Cockroft Sangamo BioSciences, Inc. Phase 1/2 Completed 5
Bijan Nejadnik SanBio, Inc. Phase 2 Completed 163
Gayatri Rao Rocket Pharmaceuticals, Inc. Phase 1 Closed 1
  • Immune Disease
  • Leukocyte Adhesion Deficiency
Kinnari Patel Rocket Pharmaceuticals, Inc. Phase 1/2 Active, not recruiting 9
  • Multiple Myeloma
Rajesh Belani Poseida Therapeutics, Inc. Phase 1 Closed 105
  • Leukemia, Acute Myeloid (AML)
Colleen Delaney Nohla Therapeutics Inc Phase 2 Closed 146
  • Epilepsy
Cory Nicholas Neurona Therapeutics Phase 1 Recruiting 40
Daniel Brennan Medeor Therapeutics, Inc. Phase 3 Active, not recruiting 30
Francois Binette Lineage Cell Therapeutics Inc. Phase 1/2 Completed 25
Henry Klassen jCyte, Inc Phase 2 Completed 84
Henry Klassen jCyte, Inc Phase 2 Completed 84
Anthony Gringeri ImmunoCellular Therapeutics Phase 3 Suspended 414
  • Leukemia, Acute Myeloid (AML)
Joseph Woodard Immune-Onc Therapeutics Phase 1 Recruiting 119
Jeffrey Lawson Humacyte, Inc. Phase 3 Active, not recruiting 355
Jeffrey Lawson Humacyte, Inc. Phase 3 Recruiting 240
Jane Lebkowski Geron Corporation Phase 1 Completed 5
  • Leukemia, Acute Myeloid (AML)
Mark Chao Forty Seven Inc. Phase 1 Active, not recruiting 258
Mark Chao Forty Seven Inc. Phase 1/2 Completed 78
William Kennedy Excision BioTherapeutics Phase 1 Recruiting 9
Pierre Caudrelier ExCellThera Inc. Phase 1 Withdrawn N/A
Leo Wang City of Hope, Beckman Research Institute Phase 1 Recruiting 18
Christine Brown City of Hope, Beckman Research Institute Phase 1 Active, not recruiting 82
De-Fu Zeng City of Hope, Beckman Research Institute Phase 1 Recruiting 6
Jana Portnow City of Hope, Beckman Research Institute Phase 1 Launching N/A
John Zaia City of Hope, Beckman Research Institute Phase 1 Active, not recruiting 12
Saul Priceman City of Hope, Beckman Research Institute Phase 1 Recruiting 39
John Zaia City of Hope, Beckman Research Institute Phase 1 Launching N/A
Michael Pulsipher Children's Hospital of Los Angeles Phase 1/2 Active, not recruiting 60
William van der Touw Celularity Inc Phase 1/2 Active, not recruiting 86
Clive Svendsen Cedars-Sinai Medical Center Phase 1 Launching N/A
Clive Svendsen Cedars-Sinai Medical Center Phase 1/2 Completed 18
Clive Svendsen Cedars-Sinai Medical Center Phase 1 Recruiting 16
  • Pulmonary Hypertension
  • Vascular Disease
Michael Lewis Cedars-Sinai Medical Center Phase 1/2 Active, not recruiting 26
Linda Marban Capricor, Inc Phase 2 Completed 25
Rachel Smith Capricor, Inc Phase 2 Closed 156
Geoff Symonds Calimmune, Inc. Phase 1/2 Completed 13
Kristen Johnson Calibr Phase 1 Completed 60
William Sietsema Caladrius Biosciences Phase 2 Completed 113
Robert Dillman Caladrius Biosciences Phase 3 Closed 4
Ralph Kern BrainStorm Cell Therapeutics Phase 3 Completed 263
Krystof Bankiewicz Brain Neurotherapy Bio Phase 1 Active, not recruiting 11
David Williams Boston Children's Hospital Phase 2 Active, not recruiting 10
Pamela Contag BioEclipse Therapeutics INC. Phase 1 Recruiting 24
Edward Kavalerchik Angiocrine Bioscience, Inc. Phase 1 Completed 10
  • B cell cancers
Paul Finnegan Angiocrine Bioscience, Inc. Phase 3 Recruiting 148
Edward Kavalerchik Angiocrine Bioscience, Inc. Phase 1 Completed 42
Icon for XLSX export